Ocumension Therapeutics logo

Ocumension Therapeutics(SEHK) 1477

Market CapHK$4.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-87%
5 Year-74%
1 Year-35%
1 Month-9%
HK$4.89
-0.31%
-0.01Today
Ocumension Therapeutics last closing stock price
MetricPriceDate
Last closeHKD 4.892026-10-14
Ocumension Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.32%HKD 5.222026-10-07
1 month-9.28%HKD 5.392026-09-14
3 month-21.38%HKD 6.222026-07-16
Year to date-33.92%HKD 7.402025-12-31
1 year-35.49%HKD 7.582025-10-14
3 year-37.94%HKD 7.882023-10-13
5 year-73.65%HKD 18.562021-10-15
Since inception-86.76%HKD 37.002020-07-10

Ocumension Therapeutics Financials at a Glance

Market Cap

HK$4.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.48B

Net Income (TTM)

-CN¥374.77M

EPS (TTM)

-HK$0.18

P/E Ratio

-27.58

Dividend

HK$0.00

Beta (Volatility)

0.03 (Low)

Price

HK$4.89

Volume

251,500

Open

HK$5.01

Previous Close

HK$4.90

Daily Range

HK$4.86 - HK$5.01

52-Week Range

HK$4.04 - HK$8.94

Estimated Earnings Date

Mar 19, 2027

1477 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ocumension Therapeutics

Ocumension Therapeutics is a biotechnology company based in the People's Republic of China, specializing in ophthalmic pharmaceuticals. The company focuses on developing and commercializing innovative therapeutic solutions for various eye conditions, aiming to improve patient outcomes in the field of ophthalmology.

Products and Services
  • Therapeutic solutions for eye disorders including glaucoma and dry eye syndrome
  • Extensive pipeline with 20 drug assets targeting multiple ophthalmic conditions
  • Research and development initiatives aimed at advancing eye care treatments
Growth Outlook
  • Recent quarterly revenue reached CNY 423.7 million, indicating strong market demand
  • Significant investment in R&D, with expenses of CNY 32.3 million in the latest quarter
  • Market capitalization of approximately CNY 4.1 billion supports future growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 1.5 billion, showcasing consistent growth
  • Current ratio of 3.31 indicates strong liquidity position
  • Net income for the latest quarter was CNY -99 million, reflecting ongoing investment in growth
Ocumension Therapeutics operates in a dynamic and growing sector, focusing on innovative treatments for eye diseases. The company's commitment to research and development is evident in its substantial investment in R&D, which is crucial for maintaining a competitive edge in the biotechnology industry. The recent revenue figures highlight the company's ability to capture market demand, while the strong liquidity position suggests that it is well-equipped to navigate future challenges. Despite reporting a net loss in the latest quarter, the focus on growth and innovation positions Ocumension Therapeutics favorably for potential investors looking for opportunities in the healthcare sector.
AI Generated • Oct 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

552

CEO

Ye Liu

Website

www.ocumension.com

Headquarters

Suzhou, JS, CN

1477 Financials

Key Financial Metrics (TTM)

Gross Margin

47.19%

Operating Margin

-13.27%

Net Income Margin

-13.44%

Return on Equity

-3.44%

Return on Capital

-4.14%

Return on Assets

-3.04%

Earnings Yield

-3.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$4.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

823.01M

Volume

251.50K

Avg. Volume

808.45K

Financials (TTM)

Gross Profit

CN¥672.29M

Operating Income

-CN¥404.52M

EBITDA

-CN¥130.12M

Operating Cash Flow

-CN¥173.74M

Capital Expenditure

-CN¥295.71M

Free Cash Flow

-CN¥469.45M

Cash & ST Invst.

CN¥268.31M

Total Debt

CN¥288.55M

Ocumension Therapeutics Performance Analysis

Ocumension Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 184,847,630173.2%
20232023-12-31CNY 272,235,04247.3%
20242024-12-31CNY 452,454,19966.2%
20252025-12-31CNY 872,338,54292.8%
Ocumension Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3149.0%
Q22025-06-3017.8%
Q42025-12-3173.6%
Q22026-06-30-17.0%
Ocumension Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.7443.4%
20232023-12-31CNY -0.65-12.7%
20242024-12-31CNY -0.43-34.2%
20252025-12-31CNY -0.22-48.8%
Ocumension Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3130.4%
Q22025-06-30-6.3%
Q42025-12-3180.4%
Q22026-06-30-259.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥423.72M

+152.8%

Gross Profit

CN¥185.51M

+87.0%

Gross Margin

43.78%

N/A

Market Cap

HK$4.02BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$6.61M

N/A

Employees

608

N/A

Net Income

-CN¥99.02M

+34.6%

EBITDA

-CN¥20.57M

+83.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥268.31M

-72.4%

Total Debt

CN¥288.55M

+1781.3%

Accounts Receivable

CN¥337.96M

+123.2%

Inventory

CN¥61.00M

-22.6%

Long Term Debt

CN¥192.32M

+7151.7%

Short Term Debt

CN¥96.25M

+658.7%

Return on Assets

-3.04%

N/A

Return on Invested Capital

-3.22%

N/A

Free Cash Flow

-CN¥17.40M

+86.9%

Operating Cash Flow

-CN¥4.01M

+96.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$14.72-6.48%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$127.57-0.65%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$33.99+1.06%

Questions About 1477

What is the current price of Ocumension Therapeutics?

Ocumension Therapeutics is trading at HK$4.89 per share.

What is the 52-week range for Ocumension Therapeutics?

Over the past 52 weeks, Ocumension Therapeutics has traded between HK$4.04 and HK$8.94.

How much debt does Ocumension Therapeutics have?

As of the most recent reporting period, Ocumension Therapeutics reported total debt of CN¥208.88M.

How much cash does Ocumension Therapeutics have on hand?

Ocumension Therapeutics reported CN¥420.42M in cash and cash equivalents in its most recent financial results.

What is Ocumension Therapeutics’s dividend yield?

Ocumension Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services